Ex vivo interleukin-12-priming during CD8 + t cell activation dramatically improves adoptive t cell transfer antitumor efficacy in a lymphodepleted host

Journal of the American College of Surgeons

Volumn 214, Issue 4, 2012, Pages 700-707

  Rubinstein, Mark P ^a   Cloud, Colleen A ^a   Garrett, Tracy E ^a   Moore, Caitlin J ^a   Schwartz, Kristina M ^a   Johnson, C Bryce ^a   Craig, David H ^a   Salem, Mohamed L ^b   Paulos, Chrystal M ^a   Cole, David J ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Tanta University   (Egypt)

Author keywords

ACT; adoptive cellular therapy; CTX; cyclophosphamide; IFN; IL; interferon; interleukin; T cell receptor; TCR

Indexed keywords

CYCLOPHOSPHAMIDE; GAMMA INTERFERON; GLYCOPROTEIN GP 100; GRANZYME B; INTERLEUKIN 12;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL EFFECTIVENESS; CROSS PRESENTATION; EX VIVO STUDY; LYMPHOCYTE DEPLETION; MELANOMA B16; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR LOCALIZATION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; FEMALE; FLOW CYTOMETRY; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; MICE; MICE, INBRED C57BL; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84863419718     PISSN: 10727515     EISSN: 18791190     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2011.12.034     Document Type: Article

References (41)

1. S.A. Rosenberg Karnofsky Memorial Lecture The immunotherapy and gene therapy of cancer J Clin Oncol 10 1992 180 199
2. S.A. Rosenberg, B.S. Packard, P.M. Aebersold Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma A preliminary report N Engl J Med 319 1988 1676 1680 (Pubitemid 19015247)
3. S.A. Rosenberg, J.R. Yannelli, J.C. Yang Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2 J Natl Cancer Inst 86 1994 1159 1166 (Pubitemid 24249302)
4. M.E. Dudley, J.R. Wunderlich, J.C. Yang Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma J Clin Oncol 23 2005 2346 2357 (Pubitemid 46218728)
5. H.E. Heslop, K.S. Slobod, M.A. Pule Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients Blood 115 2010 925 935
6. R.A. Morgan, M.E. Dudley, J.R. Wunderlich Cancer regression in patients after transfer of genetically engineered lymphocytes Science 314 2006 126 129 (Pubitemid 44547756)
7. L.A. Johnson, R.A. Morgan, M.E. Dudley Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen Blood 114 2009 535 546
8. M. Kalos, B.L. Levine, D.L. Porter T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced Leukemia Sci Transl Med 3 2011 95ra73
9. M.D. McKee, A. Fichera, M.I. Nishimura T cell immunotherapy Front Biosci 12 2007 919 932 (Pubitemid 46846867)
10. M.E. Dudley, S.A. Rosenberg Adoptive-cell-transfer therapy for the treatment of patients with cancer Nat Rev Cancer 3 2003 666 675 (Pubitemid 37328821)
11. M.E. Dudley, J.R. Wunderlich, T.E. Shelton Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients J Immunother 26 2003 332 342 (Pubitemid 36858717)
12. C.H. June Principles of adoptive T cell cancer therapy J Clin Invest 117 2007 1204 1212 (Pubitemid 46718405)
13. S.A. Rosenberg, N.P. Restifo, J.C. Yang Adoptive cell transfer: a clinical path to effective cancer immunotherapy Nat Rev Cancer 8 2008 299 308 (Pubitemid 351430867)
14. C.H. June Adoptive T cell therapy for cancer in the clinic J Clin Invest 117 2007 1466 1476 (Pubitemid 46871329)
15. C.A. Klebanoff, L. Gattinoni, P. Torabi-Parizi Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells Proc Natl Acad Sci U S A 102 2005 9571 9576 (Pubitemid 40981722)
16. R. Perret, F. Ronchese Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours? Tissue Antigens 72 2008 187 194
17. D.E. Speiser, P. Romero Toward improved immunocompetence of adoptively transferred CD8+ T cells J Clin Invest 115 2005 1467 1469 (Pubitemid 40814653)
18. L. Gattinoni, C.A. Klebanoff, D.C. Palmer Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells J Clin Invest 115 2005 1616 1626 (Pubitemid 40814670)
19. C. Berger, M.C. Jensen, P.M. Lansdorp Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates J Clin Invest 118 2008 294 305
20. J. Zhou, X. Shen, J. Huang Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy J Immunol 175 2005 7046 7052 (Pubitemid 41598952)
21. M.V. Maus, B. Kovacs, W.W. Kwok Extensive replicative capacity of human central memory T cells J Immunol 172 2004 6675 6683 (Pubitemid 38669103)
22. J.M. Curtsinger, D.C. Lins, M.F. Mescher Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function J Exp Med 197 2003 1141 1151 (Pubitemid 36570069)
23. J. Chang, J.H. Cho, S.W. Lee IL-12 priming during in vitro antigenic stimulation changes properties of CD8 T cells and increases generation of effector and memory cells J Immunol 172 2004 2818 2826 (Pubitemid 38263666)
24. R.R. Rao, Q. Li, K. Odunsi, P.A. Shrikant The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin Immunity 32 2010 67 78
25. C.M. Diaz-Montero, S. El Naggar, A. Al Khami Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8(+)CD62L (hi) cells and results in superior anti-tumor activity in a tolerogenic murine model Cancer Immunol Immunother 57 2008 563 572 (Pubitemid 351170539)
26. D.N. Lisiero, H. Soto, L.M. Liau, R.M. Prins Enhanced sensitivity to IL-2 signaling regulates the clinical responsiveness of IL-12-primed CD8(+) T cells in a melanoma model J Immunol 186 2011 5068 5077
27. M.L. Salem, A.N. Kadima, S.A. El-Naggar Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells J Immunother 30 2007 40 53 (Pubitemid 46052202)
28. M.L. Salem, C.M. Diaz-Montero, A.A. Al-Khami Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C) J Immunol 182 2009 2030 2040
29. M.L. Salem, D.J. Cole Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination Cancer Immunol Immunother 59 2010 341 353
30. W.W. Overwijk, M.R. Theoret, S.E. Finkelstein Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells J Exp Med 198 2003 569 580 (Pubitemid 37040391)
31. M.P. Rubinstein, A.N. Kadima, M.L. Salem Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells J Immunol 169 2002 4928 4935 (Pubitemid 35217158)
32. M.P. Rubinstein, N.A. Lind, J.F. Purton IL-7 and IL-15 differentially regulate CD8+ T-cell subsets during contraction of the immune response Blood 112 2008 3704 3712
33. J. Valenzuela, C. Schmidt, M. Mescher The roles of IL-12 in providing a third signal for clonal expansion of naive CD8 T cells J Immunol 169 2002 6842 6849 (Pubitemid 36899269)
34. S.J. Szabo, S.T. Kim, G.L. Costa A novel transcription factor, T-bet, directs Th1 lineage commitment Cell 100 2000 655 669
35. Q. Li, C. Eppolito, K. Odunsi, P.A. Shrikant IL-12-programmed long-term CD8+ T cell responses require STAT4 J Immunol 177 2006 7618 7625 (Pubitemid 44846276)
36. W. Zheng, R.A. Flavell The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells Cell 89 1997 587 596 (Pubitemid 27511769)
37. J.M. Curtsinger, D.C. Lins, C.M. Johnson, M.F. Mescher Signal 3 tolerant CD8 T cells degranulate in response to antigen but lack granzyme B to mediate cytolysis J Immunol 175 2005 4392 4399 (Pubitemid 41361974)
38. P. Agarwal, A. Raghavan, S.L. Nandiwada Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory J Immunol 183 2009 1695 1704
39. M.J. Dobrzanski, J.B. Reome, R.W. Dutton Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases J Immunol 162 1999 6671 6680 (Pubitemid 29309392)
40. C.S. Hinrichs, A. Kaiser, C.M. Paulos Type 17 CD8+ T cells display enhanced antitumor immunity Blood 114 2009 596 599
41. P. Muranski, A. Boni, P.A. Antony Tumor-specific Th17-polarized cells eradicate large established melanoma Blood 112 2008 362 373